|
Patrick Bedford
Manager, Clinical translation & regulatory affairs, CCRM
Patrick has over ten years of experience interpreting federal regulatory requirements for emerging biotech products, including cell and gene therapies. In August, 2016, he moved to Toronto to join CCRM as Manager, Clinical Translation & Regulatory Affairs, where he helps regenerative medicine researchers and developers navigate regulatory pathways and progress to the clinic.
Prior to CCRM, Patrick worked for the Biologics and Genetic Therapies Directorate (BGTD) at Health Canada, where he helped to develop a Guidance for Sponsors: Information and Submission Guidance for Subsequent Entry Biologics (SEBs or “biosimilars”); led a project to revise the Guidance Document for Cell, Tissue and Organ Establishments - Safety of Human Cells, Tissues and Organs for Transplantation; and led the development of the Guidance Document: Preparation of Clinical Trial Applications for use of Cell Therapy Products in Humans. Patrick also worked on international regulatory harmonization initiatives and chaired and represented BGTD on classification committees.
Patrick completed an Honours Bachelor of Health Sciences degree at the University of Western Ontario, a Master’s degree in Bioethics and Health Law at the University of Otago, and obtained a Regulatory Affairs Certificate from the Regulatory Affairs Professional Society.
|
 |
John C. Bell, PhD
Senior Scientist, Centre for Innovative Cancer Research, Ottawa Hospital Research Institute
Professor, Departments of Medicine and Biochemistry, Microbiology & Immunology, University of Ottawa
Dr. John Bell received his PhD from McMaster University in 1982. The three years that followed, he trained as a post-doctoral fellow at the University of Ottawa and then at the Medical Research Council in London, England. Dr. Bell began his independent research career at McGill University in 1986 and moved to the University of Ottawa, Department of Medicine, in 1989. He is a member of the Center for Cancer Therapeutics at The Ottawa Hospital Cancer Center, a Senior Scientist with the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox funded group from across Canada that is developing virus based cancer therapeutics and is the Director of the Biotherapeutics Program for the Ontario Institute for Cancer Research. He is the Scientific Director of the recently awarded National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and is a fellow of the Royal Society of Canada.
|
 |
Dominic Bowers
Head of Clinical Operations & Development, Catapult
Dominic Bowers is Head of Clinical at the Cell and Gene Therapy Catapult. He is responsible for oversight and delivery of a range of clinical programs within oncology, critical care and surgical specialities that encompass different technologies within the regenerative medicine field. He additionally provides clinical development expertise with clinical trial strategic planning and design implementation across a broad range of indications. Dominic previously worked as an Anaesthetist and Critical Care Physician at a senior level, most recently as a clinical fellow in General Anaesthesia whilst performing clinical development activities. A core part of his career has been devoted to the design and execution of clinical trials at Quintiles within a range of Internal Medicine specialities including Inflammatory Bowel Disease and Acute Care and Pain specialities. He has held posts as a Medical Director and Chair of the Acute Care and Pain Centre of Excellence at Quintiles. Dominic’s experience includes early phase work through to registration trial experience with small molecules, biologics, gene modified therapies and tissue engineered surgical trials.
Dominic studied Medicine at the University of Sheffield, and holds the Diploma in Pharmaceutical Medicine (UK) and is a Member of the Royal College of Anaesthetists (UK)
|
|
Paul Bowles, PhD
Development Scientist, GE Cell Therapy Technologies
Dr. Paul Bowles is a Development Scientist for GE Healthcare in their Cell Therapy Division. Paul completed his PhD in Leeds Institute of Molecular Medicine (University of Leeds) in the laboratories of Professor Eric Blair and Dr. Graham Cook, studying the Natural Killer Cells recognition of virally transformed and cancerous cells. After finishing his PhD, he spent three years working at GE Healthcare Cardiff UK, in their Cell Therapy division working developing new products for adoptive immunotherapies. Last year he moved to the new collaboration between GE Healthcare and CCRM which aim is to accelerate development and accessibility of cell manufacturing technologies.
|
|
Jonathan Bramson, PhD
Professor, Pathology and Molecular Medicine, McMaster University
Assistant Dean, Research Infrastructure, Faculty of Health Sciences
Director, Fraunhofer Project Centre for Biomedical Engineering and Advanced Manufacturing
Canada Research Chair in Translational Cancer Immunology
Jonathan Bramson, PhD, is a Professor in the Department of Pathology and Molecular Medicine and the Assistant Dean, Research Infrastructure of the Faculty of Health Sciences. He holds a Tier I Canada Research Chair in Translational Cancer Immunology and the John Bienestock Chair in Molecular Medicine. The Bramson lab is focused on developing methods to direct cancer patients’ immune systems to attack their tumors. Most recently, the lab developed a novel chimeric receptor platform to re-direct T cells to attack tumors, which will be the topic of his seminar. The Bramson lab works closely with clinical partners at the Juravinski Hospital and colleagues across Canada to optimally develop these novel strategies to address unmet needs within the cancer community in Southern Ontario. Together, Bramson and his colleagues have established an infrastructure within Ontario, which includes GMP production and GLP correlative assays, for conducting clinical trials of novel cancer immunotherapies that is unparalleled in Canada. Bramson is also the inaugural director of the Fraunhofer Project Centre for Biomedical Engineering and Advanced Manufacturing at McMaster University (BEAM), which is an international joint venture with the Fraunhofer Society of Germany. Situated in Hamilton, BEAM is focused on commercialization of promising technologies in the areas of cell therapies, diagnostics and biomaterials.
|
 |
William Brock, Ad. E.
Survivant d'une leucémie aigüe
Vice-président, Conseil d'administration de CellCAN
Avocat, Partenaire, Davies
William Brock est associé au sein du cabinet d’avocats Davies Ward Phillips & Vineberg LLP. En septembre 2004, on lui a diagnostiqué une leucémie myéloïde aiguë, sept ans après le décès de son père de cette même maladie. M. Brock a survécu grâce aux soins compétents des médecins et du personnel soignant de l’Hôpital Maisonneuve-Rosemont de Montréal, après avoir reçu un don de moelle osseuse de son frère. Une fois guéri, il a contribué à la mise sur pied du Fonds William Brock en enseignement et recherche sur les cancers du sang. Au printemps 2010, à l’occasion du 5e anniversaire de sa greffe de moelle osseuse, il a parcouru l’Europe en vélo afin de lever des fonds pour la recherche. Il a publié un livre intitulé Portraits d’espoir, pour soutenir le Fonds et redonner de l’espoir aux patients atteints de cancers du sang. En mars 2015, avec son épouse, il a lancé la Chaire Maryse et William Brock pour la recherche appliquée en greffe de cellules souches.
|
|
Tania Bubela, JD, Ph.D., B.Sc. (Mention d'honneur)
Professeure, Département de la santé publique, Université d'Alberta
Dr Bubela (BSc (Hons), PhD, JD) is Professor in the School of Public Health and Adjunct Professor in the Alberta School of Business at the University of Alberta, Canada. She joined the faculty of the U Alberta in 2004 after clerking for The Honourable Louise Arbour at the Supreme Court of Canada, articling at Field Law LLP in Edmonton, and being called to the bar (Law Society of Alberta) in 2005. Her research program in intellectual property and health law related to translational biomedical research brings together her legal training and a PhD in biology and expertise in genetics and molecular biology. Her research program focuses on large collaborative science networks in genomics, gene therapy, and stem cell biology, addressing barriers to the effective translation of new technologies and the introduction of precision medicine. These are varied and include ethical issues, effective communication of risks and benefits among stakeholder groups, commercialization and regulation. She provides advice for Government Health and Science agencies as well as life sciences research communities, and patient organisations. Her research is funded by the Canadian Institutes of Health Research, the Canadian Stem Cell Network, BioCanRx, Genome Canada, and Alberta Innovates - Health Solutions, among others. She co-leads the PACEOMICS program on the development of cost-effective personalized medicine and the Alberta Ocular Gene Therapy Team, which is developing novel gene therapies and conducting a phase I clinical trial of the NighstaRx AAV2-REP1 product for choroideremia. She has nearly 100 publications in law, ethics and science policy journals including Nature, Nature Biotechnology, Cell Stem Cell, PLoS Biology, Trends in Biotechnology, American Journal of Bioethics and Science Translational Medicine.
|
|
Dr Lambert Busque
Chief Medical Officer, C3i
Chief of Molecular Diagnostic, Hôpital Maisonneuve-Rosemont
Chief of the Diagnostic Program of Medical Biology, Hôpital Maisonneuve-Rosemont
Dr Busque is a practicing hematologist at Hôpital Maisonneuve-Rosemont (HMR), and serves as Chief of Molecular diagnostic and Chief of HMR's Diagnostic Program of Medical biology being altogether responsible for 300 employees and managing a budget of 30 Million$/year. He sits on several Quebec government regulatory committees such as the Institut National d'Excellence en Santé et Services Sociaux (INESSS). He is the co-founder of the Quebec CML Registry and a founder and current president of the non-for-profit organization GQR-LCM/NMP (Groupe québécois de recherche en leucémie myéloide chronique et en néoplasies myéloprolifératives) where he successfully built a network comprising 20 oncology centers in the province of Quebec. Dr. Busque is a sought after as a key opinion leader (KOL), and his advice and expertise are critical to numerous pharmaceutical companies.
Dr Busque has over 20 years of biotechnology and clinical research experience. He founded and was the medical director at ProDNA diagnostics, a molecular diagnostics provider, which was later sold to Warnex (now known as Dynacare). He founded and was the President of HemaX Genome, a company focused on the identification of genes of medical interest localized on the X chromosome. HemaX genome was later acquired by Emerillon Therapeutics Inc. During these tenures, Dr Busque acquired experience in raising venture capital funds and in developing international collaborations.
Dr. Lambert Busque obtained his Medical Degree from the Université de Montréal in 1986 and completed residencies in internal medicine and hematology before completing a post-doctoral fellowship at Harvard in molecular hematology. He has since continued on as an accomplished clinician-researcher and with a specific interest in translational hematology. He has published in prestigious journals such as the New England Journal of Medicine, Nature Genetics, Blood and the Journal of Clinical Investigation. He is Professor of Medicine at the Université de Montréal.
|
|
Joanne Castonguay
Consultante de recherche, CIRANO
Directrice de la recherche, Institut de recherche en politiques publiques
Professeur associée, Pôle santé HEC Montréal
Joanne Castonguay est directrice de recherche, économie canadienne et enjeux émergeants à l’IRPP. Économiste, elle s’intéresse aux politiques publiques notamment en gouvernance des systèmes depuis plus de 15 ans. Avant de se joindre à l’IRPP, elle a été vice-présidente adjointe au Centre Interuniversitaire en recherche et analyse des organisations (CIRANO), directrice de la recherche de l’Association médicale du Québec, conseillère au Fonds de recherche en santé du Québec et Directrice de projet chez SECOR conseil. Reconnue pour son expertise, notamment sur la gouvernance des grands projets, l’orientation de la recherche, le transfert des innovations, les mécanismes de gouvernance en santé et la gestion des risques socio-politiques, elle siège sur différents comités d’experts et donne régulièrement des conférences. Elle est l’auteur de plusieurs rapports et articles de vulgarisation sur ces questions. Au cours de la dernière décennie, elle a influencé le développement de projets de loi québécois par ses publications dont la série sur la gouvernance des grands projets d’infrastructure publique et l’Analyse comparative des mécanismes de financement des hôpitaux. Plus récemment, Joanne travaille sur les politiques qui favorise l’intégration des innovations.
|
|
Michèle de Guise, M.D., M.M. (IMHL), FRCPC
Directrice, Direction des services de santé et de l'évaluation des technologies, Institut national d'excellence en santé et en services sociaux (INESSS)
Michèle de Guise est directrice des services de santé et de l’évaluation des technologies à l’Institut national d’excellence en santé et services sociaux (INESSS), depuis juillet 2015. Cardiologue de formation, diplômée de l'Université de Montréal, elle a poursuivi sa formation en réadaptation cardiaque, échographie puis prise en charge des clientèles de patients avec insuffisance cardiaque terminale notamment par support mécanique et transplantation, à Montréal, Londres, Philadelphie puis Cleveland. Elle a par la suite travaillé comme cardiologue au Centre hospitalier de l'Université de Montréal (CHUM). À titre de clinicienne, elle y a proposé et implanté la clinique d'insuffisance cardiaque et le programme de réadaptation cardiaque pour les clientèles à haut risque. Sur le plan managérial, après avoir complété une maitrise en gestion à l'université McGill (International Master in Health Leadership), elle a successivement occupé, toujours au CHUM, les postes de directrice de la promotion de la santé, de directrice de la qualité, de la promotion de la santé et de l'expérience patient puis de directrice médicale adjointe responsable de la qualité, et de l'évolution de la pratique.
|
|
Tyson Garbe
Assistant Director, Trade & Investment
Japan External Trade Organization (JETRO Toronto)
Tyson Garbe is the Assistant Director of Trade & Investment at JETRO Toronto and is responsible for investment to Japan activities in the manufacturing and healthcare sectors.
With over 18 year experience working on Japan trade and investment issues, Tyson has looked after projects related to automotive, aerospace, biotech, cleantech, ICT, nanotech and a variety of other sectors. Other duties include assisting Japanese companies to find export opportunities in the Canadian market, facilitating regional partnership programmes between Canada and Japan, liaising with other government organizations and media relations activities.
Born in Montreal, Tyson was raised in London, England where he stayed until completing his MA in International Studies. He then spent five years working in Japan before returning to Canada.
Recently, JETRO has paid particular attention to the field of Regenerative Medicine since the Japanese government’s introduction of an expedited approval system for RM products as well as other reforms related to the supply of stem cells in Japan. JETRO is eager to support foreign companies looking to enter the Japanese market.
|
 |
Adrian Gee, Ph. D.
Professeur, Medicine and Pediatrics
Directeur, Clinical Applications Lab, Baylor College of Medicine, Houston, USA
Dr. Adrian Gee received his bachelor's degree from the University of Birmingham, England, and his Ph.D. from the University of Edinburgh, Scotland. He did his postdoctoral training at the National Institutes of Health, and the University of Toronto, before taking a faculty position at the University of Florida. There he performed some of the first applications of immunomagnetic tumor purging in the United States, and his laboratory became a central cell processing facility for this procedure. He joined Baxter Healthcare in 1987, where he worked on the development of the MaxSep and Isolex magnetic cell separators. He co-founded the International Society for Hematotherapy and Graft Engineering (ISHAGE, now ISCT), and the Journal of Hematotherapy (now Cytotherapy) in 1992. From 1992 to 1997 he helped establish the stem cell transplantation program at the University of South Carolina. He then directed the Cell Processing Laboratory at the University of Texas MD Anderson Cancer Center until 1999, when he joined the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine in Houston. The CAGT houses GMP manufacturing facilities for vectors and cell therapy products. He was involved in the development of standards for the collection processing and transplantation of hematopoietic stem cells for the Foundation for the Accreditation of Cell Therapy (FACT), the AABB and the National Marrow Donor Program. He has written more than 180 scientific articles and has authored and edited a number of books on graft engineering and stem cell processing. He currently is a member of the HRSA committee on Blood Stem Cell Transplants, the FACT committee on Regenerative Medicine and the Program Review Group for the California Institute of Regenerative Medicine.
|
|
David Guay
Research Director, Feldan Therapeutics
David Guay is the Research Director at Feldan Therapeutics since 2009. David Guay received his PhD in molecular and cell biology from Laval University for its research on the implication of a transcription factor in DNA repair and chemotherapy resistance mechanisms. He held a postdoctoral fellowship from McGill University in the chemical engineering where he developed a DNA delivery technique based on a non-thermal plasma technology. His research at Feldan Therapeutics focuses on the “Feldan Shuttle”, a peptide-based technology designed to deliver native proteins, namely transcription factors, antibodies and CRISPR nucleases, in therapeutic cells.
|
|
Dr Philippe Hénon
President and Scientific Director, CellProthera
Philippe HENON, MD, Hematologist, graduated from the School of Medicine, Paris, France, in 1968. Assistant Professor of Hematology/Assistant Director of the Department of Hematology, Paris VII University and Hôpital Lariboisière, Paris (1970-1978). Head of the Department of Hematology in Mulhouse Hospitals, France (1979). Founder/Director since 1987 of the “Institut de Recherche en Hématologie et Transplantation”, Mulhouse. Professor and Director of the Educational Program on Hematopoiesis and Cell Therapy at the University of Haute-Alsace, Mulhouse (2000-2010). Visiting Professor of Cell Therapy at the University of Lincoln, UK (2003-2007) and at the New York Medical College, USA (2006-2010). Founder, President and CSO of CellProthera, Med-tech company launched in June 2009.
Pioneer in 1985, in the field of peripheral blood stem cells (PBSC) characterization, evaluation and clinical use. Laureate of an “Excellency Achievement Award of the Millenium” in the field of Hematopoiesis, handed over by Professor Don Thomas, 1990 Nobel Laureate, New York, USA, 2000. For the past 15 years, he more specially focused on the use of PB-CD34+ stem cells for cardiac repair after myocardial infarct..Member of over ten International Scientific Societies and of numerous Scientific Committees in international meetings. Author of more than 160 publications in international peer-reviewed journals and of 4 books focused on PBSC transplantations, he gave more than 220 communications/conferences worldwide, and organized and chaired 10 international meetings, mainly on PBSC transplantations
|
|
Queenie Jang, BSc (Pharmacy), MBA
Executive Director, International Society for Cell Therapy (ISCT)
Through her extensive business leadership and management experience in the biomedical/pharmaceutical industry in both private and public companies, Queenie has led ISCT’s emergence as the leading global cell therapy society focussed in regulatory, commercial and academic thought leadership. 2017 celebrates the 25th Anniversary of ISCT through the Annual Meeting in London, UK. Attracting over 1500 international delegates representing over 50 countries, the ISCT Annual Meeting is a hallmark of the state of the art translational science and global business development for the host city and region. Ms. Jang holds a B.Sc.(Pharmacy) from the University of British Columbia and an MBA from Richard Ivey School of Business at the University of Western Ontario.
|
|
Dr Armand Keating
Director
Cell Therapy Program at the University Health Network, Toronto
Dr Armand Keating est directeur du programme de Thérapie cellulaire au University Health Network de Toronto. Il a obtenu son doctorat en médecine à l'Université d'Ottawa et a suivi une formation en médecine interne et en hématologie à l'Université de Toronto. Il a reçu une bourse de recherche de l'Université de Washington et du Fred Hutchinson Cancer Research Center de Seattle (État de Washington). Le docteur Keating s’intéresse particulièrement à la thérapie cellulaire anticancer, à la greffe de sang et de moelle osseuse, à la leucémie, au lymphome et à la médecine régénératrice. En 1986, il a mis en place le Programme de greffe de moelle osseuse et de sang autologue de l'Université de Toronto. Le Dr Keating a fait partie et présidé plusieurs comités d'évaluation scientifique, notamment pour le US National Cancer Institute, l'Institut national du cancer du Canada et la Leukemia and Lymphoma Society. Le Dr Keating fait partie des comités de rédaction de nombreuses revues scientifiques. Il est membre fondateur de CellCAN, dont il préside le comité directeur.
|
 |
Dr Bartha Knoppers
Directrice du Centre de génomique et politiques au Département de génétique humaine
de la Faculté de médecine de l’Université McGill
Présidente du International Stem Cell Forum’s Ethics Working Party
Dre Knoppers est directrice du Centre de génomique et politiques (CGP) au Département de génétique humaine de la Faculté de médecine de l’Université McGill, à Montréal. Elle est également présidente du International Stem Cell Forum Ethics Working Party (ISCF-EWP), en plus de collaborer à deux subventions gouvernementales de base accordées par le Réseau de cellules souches (RCS) du Canada pour la recherche sur les cellules souches, les banques de cellules souches et la traduction clinique.
|
|
Nadine Kolas, PhD
Senior Policy Analyst, Health Canada
Dr. Kolas is a senior policy analyst and former research scientist with expertise in reproductive biology and the DNA damage response, as it pertains to early mechanisms of cancer development, using mouse models and cell-based genomics approaches. She received her PhD in molecular genetics from Albert Einstein College of Medicine in New York City, and conducted post-doctoral work at the Lunenfeld-Tanenbaum Research Institute in Toronto where she discovered novel post-translational modifications that modulate DNA repair. Her work has been published in journals including Science and Cell, she has held fellowships from CIHR and the Terry Fox Research Institute, and won the 2008 Polanyi Award for medicine/physiology from the Ontario government. Shifting her focus from research to knowledge translation, she turned down an offer to start her own lab in favour of policy with Health Canada and has been the senior policy analyst for advanced cell therapies in Health Canada’s Health Products and Foods Branch since the beginning of January 2017. Prior to joining the Branch she worked with an expert panel, led by Dr. David Naylor, to review the federal ecosystem supporting fundamental research in Canada; and developed policy for knowledge translation and research governance for management of Health Canada’s regulatory research programs including chemicals, nanomaterials, Northern contaminants and air pollution.
|
 |
Dr. Geoffrey Lomax Dr. PH
Senior Officer
CIRM Strategic Infrastructure (CSI)
Dr. Geoffrey Lomax is the Senior Officer for CIRM’s Strategic Infrastructure Program. The CIRM Infrastructure Program develops strategic assets to accelerated the delivery of therapies to patients with unmet medical needs. In this role, Dr. Lomax coordinates the implementation of the CIRM Alpha Clinics Network and CIRM Stem Cell Center. The Alpha Clinics are top California medical centers that deliver high-quality stem cell clinical trials. The Stem Cell Center is a CRO based in California with a dedicated focus on cell therapies. The Center provides strategic planning, regulatory, clinical operations and data management services to clinical trial sponsors. Dr. Lomax also facilitates the development of CIRM’s Medical and Ethical Standards.
|
|
Michael May, PhD
CEO, CCRM The Banting Institute
Michael May is President and Chief Executive Officer of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian, not-for-profit that develops technologies and launches new companies by supporting both academic and industry activities in the field of regenerative medicine, including cell and gene therapy. With a staff of 50, a network of academic members, 50+ industry partners, dedicated funding and facilities to develop technologies, manufacture cell product and incubate companies, CCRM is generating health and economic benefits for its stakeholders. Prior to CCRM, Michael was the President, and co-founder, of Rimon Therapeutics Ltd., a Toronto-based regenerative medicine company developing novel medical polymers that possess drug-like activity.
Michael sits on a number of boards and advisory committees including: MaRS Innovation; the Ontario Institute of Regenerative Medicine (OIRM); the Centre for the Commercialization of Antibodies and Biologics (CCAB); The Centre for Phenogenomics (TCP); the Department of Chemical Engineering and Applied Chemistry at the University of Toronto; the Industry Committee of the International Society for Stem Cell Research (ISSCR); the Executive Committee, Alliance for Regenerative Medicine (ARM); ExCellThera Ltd.; the Rick Hansen Institute Commercialization Program Advisory Committee; Toronto Region Board of Trade Life Sciences Steering Committee; the NSERC CREATE M3 Program Committee; and the Cell and Gene Therapy Insights, Editorial Advisory Board.
Dr. May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.
|
 |
Jennifer Molson
Survivor, Multiple Sclerosis Symptoms
She was diagnosed with Relapsing Remitting Multiple Sclerosis at the age of 21 in 1996. After multiple failed therapies, she took part in a clinical trial at the Ottawa Hospital funded by the MS Society Scientific Research Foundation involving stem cells at the age of 27.
The trial was a stem cell bone marrow transplant to treat Early Aggressive MS as an auto immune disease.
As of 2006, she has actively been involved with the Stem Cell Network on the Research Management Committee as a Patient Advocate, as well as, with the Canadian Stem Cell Foundation since their inception in 2009, as their first volunteer.
She is currently employed at the Ottawa Hospital since 2008 as a Research Assistant at the Ages Cancer Assessment Clinic. She has a passion for stem cell research and speaking to the public about her experience being involved in a clinical trial.
|
|
James Piret, Sc.D., FCIC
Professor, University of British Columbia
CellCAN Bioengineering Leader
Dr. Piret is a Professor in the Department of Chemical & Biological Engineering and the Michael Smith Laboratories at the University of British Columbia. He has an Applied Mathematics to Biochemistry Bachelor’s degree from Harvard and a Chemical Engineering doctoral degree from MIT. At UBC since 1989 his research focus has been on the R&D of innovative process and device technology for mammalian cell culture therapeutic protein or cell production. His multi-disciplinary research ranges from bioreactor engineering to molecular biology, often including collaborative work with scientists and industry. Dr. Piret was the founding Bioengineering leader of the Canadian Stem Cell Network as well as CellCAN.
|
 |
James Price, MBA
Président-directeur général, Fondation canadienne des cellules souches
Président-directeur général de la Fondation canadienne des cellules souches, James Price contribue depuis plus de dix ans à l’avancement de la recherche sur les cellules souches. Président fondateur de Aggregate Therapeutics Inc., une entreprise de médecine régénératrice en développement, il a aussi occupé le poste de directeur du Réseau de cellules souches. Avant de se tourner vers le secteur des cellules souches, il a été directeur de stratégies d’entreprise au sein de PricewaterhouseCoopers. Il y a collaboré à plusieurs projets de création d’entreprise, de commercialisation technologique et de recherche et développement, notamment la création des Instituts de recherche en santé du Canada et le plan de recherche stratégique du University Health Network, en plus d’aider l’Institut Rick Hansen à établir le Réseau Rick Hansen pour les lésions médullaires.
|
 |
Jerome Ritz
Directeur exécutif
Connell O'Reilly Cell Manipulation at the Dana Farber Cancer Institute, Boston, USA
A graduate of Northwestern University in Evanston Illinois, Dr. Ritz received his MD from Chicago Medical School followed by residency training in Internal Medicine at the University of Wisconsin Hospitals. Dr. Ritz subsequently completed a clinical fellowship in Hematology and Oncology at Boston’s Beth Israel Hospital and a research fellowship in Tumor Immunology at the Dana-Farber Cancer Institute. He is currently Professor of Medicine at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School.
Dr. Ritz’s major research interests have been in cancer immunology and stem cell transplantation. Studies in his laboratory have focused on immune reconstitution after hematopoietic stem cell transplantation. In this setting, donor immune cells play a critical role in the recognition and elimination of residual leukemia cells (graft versus leukemia – GVL) but immunologic targeting of normal recipient cells also leads to graft versus host disease (GVHD) and damage to normal tissues. His studies of immune reconstitution have demonstrated that donor B cells and regulatory T cells play important roles in the development of GVL and GVHD and the establishment of immune tolerance after stem cell transplantation. These observations have led to new strategies to selectively modulate immune reconstitution to improve patient outcomes after transplant.
Dr. Ritz established the Connell-O'Reilly Cell Manipulation Core Facility (CMCF) at DFCI in 1997 and is currently its Executive Director. The CMCF is a core facility of the Dana-Farber/Harvard Cancer Center and supports the adult and pediatric stem cell transplant programs at DFCI, BWH and Boston Children’s Hospital. The CMCF is a GMP processing facility that provides manufactured cellular products of various types for patients enrolled on clinical trials evaluating novel cellular therapies for cancer and other diseases. These manufactured products include cellular vaccines, immune cells for adoptive cell therapy, CAR T cells and genetically modified stem cells.
|
 |
Isabelle Rivière, Ph. D.
Directrice
Cell Therapy and Cell Engineering Facility
Memorial Sloan Kettering Cancer Center
Dr Rivière détient un doctorat en biologie cellulaire et moléculaire de l’Université de Paris. Elle a entrepris ses études supérieures à l’Institut Curie à Paris et achevé sa thèse dans le laboratoire du Dr.Mulligan à l’Institut Whitehead à Cambridge, MA. Pendant ce temps, elle a développé de nouveaux vecteurs rétroviraux pour in vivo à long terme expression de transgènes dans les cellules hématopoïétiques à l’aide de vecteurs rétroviraux MFG/SFG-basé qui sont largement utilisés dans les études cliniques pour le traitement des troubles génétiques et acquises. Elle a ensuite travaillé comme un stagiaire post-doctoral dans le laboratoire du Dr D. Littman New York University, New York. Ses études axées sur la régulation des cytokines produisent par de lymphocytes T helper in vivo. Dr Rivière a rejoint la faculté de Memorial Sloan-Kettering Cancer Center en 1999. Elle est actuellement le directeur de la Michael G. Harris thérapie cellulaire et installations de génie cellulaire où elle étudie la modification génétique de cellules hématopoïétiques d’augmenter ou de rediriger la réponse immunitaire contre les tumeurs. Son laboratoire a cellule développé des procédés de fabrication dans des conditions de GMP pour plusieurs phases I / essais cliniques II. Elle est impliquée dans le développement et la mise en œuvre du nouveau INDs et RAC/NIH demandes institutionnel Phase I et les essais cliniques de Phase II multicentriques. Elle est un membre actif de l’American Association for Cancer Research (AACR), Alliance for Regenerative Medicine (bras), American Society of Gene et thérapie cellulaire (ASGCT), société internationale pour la thérapie cellulaire (ISCT), société internationale de Stem Cell Research (ISSCR) et Institut National de l’Innovation dans la fabrication de produits biopharmaceutiques (NIIMBL).
|
|
Raelyn Rosa, MASc
Design Engineer, Octane Biotech
Raelyn Rosa is currently working for Octane Biotech as a design engineer in support of the Cocoon™ product development. With a background in Electrical and Biomedical Engineering from McMaster University, she focuses in electrical design, as well as integration of electrical, mechanical and software systems for biotech applications. She has been working together with a team of experts in the engineering and biology fields to create a product that meets the growing requirements of cell manufacturing across autologous and matched allogenic markets. Octane proposes Cocoon™ as a solution to these challenges.
|
 |
Dre Janet Rossant, MRSC
Présidente et directrice scientifique à la Fondation Gairdner
Présidente du comité de travail sur la médecine régénératrice du Conseil des Académies Canadiennes
Janet Rossant, chef émérite de la recherche à l’hôpital pour enfants SickKids et experte de renommée mondiale en biologie du développement, a entrepris en 2016 son mandat de présidente et directrice scientifique de la Fondation Gairdner. Solidement campée sur la ligne de front de l’évolution technologique, Mme Rossant a contribué à faire de l’établissement SickKids un chef de file mondial de la recherche génétique.
Mme Rossant a reçu sa formation aux universités d’Oxford et de Cambridge, au Royaume-Uni et est au Canada depuis 1977. Elle a d’abord travaillé à l’Université Brock, puis au Samuel Lunenfeld Research Institute de l’hôpital Mount Sinai à Toronto, de 1985 à 2005. Elle s’est jointe à l’hôpital SickKids en 2005. Bien connue pour ses études sur les gènes qui gouvernent le développement embryonnaire de la souris, Mme Rossant a fait œuvre de pionnière relativement aux techniques permettant de suivre le devenir des cellules et d’altérer les gènes des embryons. Ses travaux dans ce domaine trouvent encore écho aujourd’hui dans la recherche génétique médicale. Les travaux qu’elle mène actuellement portent sur le développement des cellules souches et la différenciation cellulaire au cours du développement embryonnaire, des domaines de recherche importants pour l’étude des anomalies congénitales et la médecine régénérative.
Mme Rossant a reçu plusieurs distinctions pour sa contribution à la science, y compris la médaille Ross G. Harrison (prix de reconnaissance pour l’ensemble de ses réalisations) de la Société internationale de biologistes du développement, le prix Killam en sciences de la santé, le prix March of Dimes en biologie du développement, la médaille Conklin de la Society for Developmental Biology et le prix Michael Smith du CRSNG pour la recherche en santé. Elle est membre de la Royal Society of London et de la Société royale du Canada et associée étrangère de la National Academy of Science des États-Unis. Mme Rossant a récemment reçu le 10e prix ISTT de l’International Society for Transgenic Technologies à Edinburgh, en Écosse.
|
|
Dr Denis Claude Roy
Directeur général, CellCAN
Directeur, Centre de recherche - CIUSSS de l'Est-de-Montréal
Directeur, Centre d'excellence en thérapie cellulaire
Dr Denis-Claude Roy est directeur du laboratoire de thérapie cellulaire et directeur scientifique du Centre de recherche de l’Hôpital Maisonneuve-Rosemont à Montréal. Il est également directeur général de CellCAN, professeur titulaire à l’Université de Montréal et chargé de cours à l’Université McGill. Le Dr Roy a étudié en médecine à l’Université de Montréal et suivi une formation postdoctorale en immunologie des tumeurs au Dana-Farber Cancer Institute de l’Université Harvard. Ses intérêts de recherche se concentrent sur l’immunologie des greffes de cellules souches, et plus particulièrement sur le traitement des greffons permettant d’éliminer les rejets et d’optimiser leur action anticancéreuse. Il a publié une centaine d’articles dans des revues prestigieuses, ainsi que des chapitres de livres et a formé plus de 55 étudiants à la maîtrise, au doctorat et au postdoctorat. Il a également fait partie de nombreux comités d'évaluation scientifique.
|
 |
Dr Jacques P. Tremblay
Professor, Department of Molecular Medicine, Laval University
Dr. Jacques P. Tremblay received a PhD in Neuroscience from the University of California at San Diego in 1974. Since that time, he has been at Laval University as a postdoctoral researcher, Professor and Director of the Department of Anatomy. He is currently Full Professor in the Department of Molecular Medicine. He has published over 250 scientific articles on hereditary diseases. He has worked specifically on myoblast transplantation as a treatment for Duchenne muscular dystrophy. For the last 3 years he also worked on gene correction with the CRISPR/Cas9 technology for Duchenne muscular dystrophy, Friedreich's Ataxia and Alzheimer’s disease.
|
|
Maureen Trudeau
Medical Oncologist, Sunnybrook Research Institute
Chair for the Expert Review Committee of the pan-Canadian Oncology Drug Review (pCODR)
Dr. Maureen Trudeau is a Medical Oncologist, specializing in breast cancer. She is an Affiliate Scientist at the Sunnybrook Research Institute and Professor of Medicine at the University of Toronto. As co-chair of the Breast Cancer Disease Site Group in the Program in Evidence-Based Care of Cancer Care Ontario, Dr. Trudeau is involved in practice guideline development. She has also been involved with the approval for funding of cancer provincially since 2006; and nationally since 2012; as Vice Chair and now Chair for the Expert Review Committee of the Pan Canadian Oncology Drug Review.
|
|
Sowmya Viswanathan, PhD
Assistant Professor, Institute of Biomaterials and Biomedical Engineering, University of Toronto
Affiliate Scientist, Krembil Research Institute, University Health Network
CellCAN Manufacturing Platform Leader
Dr. Viswanathan is an Affiliate Scientist at the Krembil Research Institute, University Health Network, and an Assistant Professor at the Institute of Biomaterials and Biomedical Engineering, University of Toronto. Her research interest is focused on anti-inflammatory approaches to target osteoarthritis (OA), including using proprietarily-enhanced mesenchymal stromal cells (MSCs), re-programming monocytes/macrophages and using peptide inhibitors.
As a translational scientist, Dr. Viswanathan has overseen clinical translation of over 13 cell-based therapies, including as co-Principal Investigator on an MSC trial to treat OA patients, a Canadian first. Dr. Viswanathan co-chairs a Cell Therapy Stakeholder’s Group (CTSG) that has bilateral interactions with Health Canada on shaping policy and guidelines pertaining to cell-and gene-therapies.
Dr. Viswanathan provides her expertise to Standard Council of Canada’s Mirror Committee for International Organization for Standardization (ISO TC276) on Analytical Methods and Bioprocessing and to the Standards Coordinating Body (SCB) on cell, gene therapies and tissue engineering. Dr. Viswanathan is a founding member, and team leader of the Manufacturing Committee of a network of Pan-Canadian cell manufacturing facilities called CellCAN. She is the first editor of a recently-published book on “Mesenchymal Stromal Cells: Translational Pathways towards Clinical Adoption”.
|
|
Dr Xiuyan Wang
Assistant Director
Michael G. Harris Cell Therapy and Cell Engineering Core Facility
Dr. Wang received her PhD degree in biomedical sciences with a focus on microbiology and virology from Mount Sinai School of Medicine in 2002. Her graduate studies focused on elucidating innate immune defense mechanisms during host and viral interaction in Dr. Adolfo García-Sastre’s laboratory. She found that the non-structure protein 1 (NS1) of influenza A and B viruses, and the Ebola virus VP35 protein inhibit NF-kB activation and IFN expression and demonstrated the role of these proteins as important viral virulent factors. She subsequently joined Dr. Peter Cresswell’s laboratory in the Department of Immunobiology at Yale University School of Medicine initially working as an HHMI fellow and then as the Cancer Research Institute postdoctoral associate. Her studies during her postdoctoral training focused on interferon inducible protein Viperin and demonstrated that Viperin inhibits influenza viral budding and release by changing lipid raft microdomains. She also generated transgenic and knockout animal models to facilitate the in vivo studies.
Dr. Wang joined the Michael G. Harris Cell Therapy and Cell Engineering Core Facility led by Dr. Isabelle Rivière at Memorial Sloan Kettering Cancer Center in 2007. Dr. Wang currently serves as the Assistant Director and has overseen the successful manufacturing of more than 150 clinical cell products for phase I/II clinical trials. She maintains close contact with the office of clinical research at MSK, PIs and collaborators, for all the research and clinical studies, ensuring smooth daily operations. Dr. Wang also supervises the large-scale clinical-grade retroviral production, and the process development. She and her team have established the new large-scale clinical-grade retroviral production platform using a fixed bed bioreactor. She is a member of the translational science and product development committee in the American Society of Gene and Cell Therapy (ASGCT), and a participant in the workshop of National Cell Manufacturing Consortium (GRA & Georgia Tech, NIST AMTec).
|
 |
Phil Welford
Directeur exécutif
Réseau de cellules souches
Philip Welford est le directeur général du Réseau de cellules souches depuis novembre 2013. Avant de se joindre au Réseau, il était vice-président des partenariats stratégiques chez JDRF Canada, poste qu’il a occupé pendant deux ans et demi.
Auparavant, Philip a assumé les fonctions de chef de cabinet au sein d’organismes du gouvernement fédéral. Il a notamment été chef de cabinet du ministre d’État aux Sciences et à la Technologie, du ministre d’État responsable de l’Agence fédérale de développement économique pour le sud de l’Ontario et du directeur des Affaires parlementaires pour la recherche et le développement pharmaceutique, l’association industrielle qui représente les intervenants de la recherche pharmaceutique au Canada.
Originaire d’Angleterre, Philip s’est installé au Canada en 2004. Dans son pays d’origine, il était entrepreneur dans les domaines de l’agriculture et du commerce de détail. On lui reconnaît ses excellentes qualités de leader, son expertise en optimisation des pratiques commerciales et sa passion pour le perfectionnement du personnel et la responsabilité sociale des entreprises.
|